Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086268 · ClinicalTrials.gov registry record · Phase 3
Non-small Cell Lung Cancer Study US75 (Z-PACT)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT00086268 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 250 participants.
The verdict
NCT00086268, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.
Interventions
- DRUG Carboplatin
- DRUG Taxotere
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086268
The ClinicalTrials.gov registry entry for NCT00086268 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00086268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086268 about?
NCT00086268 is a clinical study titled "Non-small Cell Lung Cancer Study US75 (Z-PACT)". This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-...
What is the current status of trial NCT00086268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2004-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00086268?
The interventions under investigation include: Carboplatin (DRUG), Taxotere (DRUG), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00086268?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.